Clinical Trial: A First-in-human (FIH), Open-Label, Dose Escalation and Expansion Cohorts Study of MC002

U.S., July 25 -- ClinicalTrials.gov registry received information related to the study (NCT07726212) titled 'A First-in-human (FIH), Open-Label, Dose Escalation and Expansion Cohorts Study of MC002' on July 10.

Brief Summary: The goal of this clinical trial is to learn if ADC drug MC002 works to treat locally advanced/metastatic solid tumors in adults. It will also learn about the safety of MC002. The main questions it aims to answer are:

Does participants tolerate the drug MC002 ? What medical problems do participants have when treating with MC002? Does participants benefit from the MC002

.

Participants will:

Intravenous infusion MC002 every 3 weeks in clinical Visit the clinic once every 3 weeks for checkups and tests Keep a diary of...